VEGFA and neoplasm: Inhibition of tumor neovascularization is an effective method to achieve metastatic suppression in lung cancer.[201] Antiangiogenic agents widely used to treat lung cancer include vascular endothelial growth factor (VEGF) inhibitors (bevacizumab), recombinant human vascular endothelial inhibitors, and small‐molecule multitargeted tyrosine kinase inhibitors (amilorotinib hydrochloride).